Managing skin toxicities related to panitumumab

Abstract

Background: Dermatologic toxicities from targeted agents such as panitumumab can interfere with cancer treatment.

Objective: We sought to evaluate the rash assessment and management in a consecutive patient cohort who received panitumumab for colorectal cancer treatment.

Methods: This was a retrospective chart review.

Results: Skin toxicity, consisting of papulopustular rash, was experienced by 32 of 34 patients. The majority (85%) developed the rash by the end of the second infusion cycle. Patients presented with a mild (41%), moderate (38%), and severe (21%) rash, and progressed to an extensive rash without appropriate treatment. A grading system was used for 65% of patients to document severity.

Limitations: Small sample size limited power in analysis. Rash severity had to be inferred based on rash description and management in 11 of the patients.

Conclusion: Dermatologic toxicities related to panitumumab are common; however, the way they are reported and managed varies among physicians. To prevent progression, toxicities must be assessed and treated early and aggressively, according to severity grading. Dermatologists could aid oncologists in choosing the best management strategies.

Keywords: Common Toxicity Criteria for Adverse Events; epidermal growth factor receptor inhibitors; panitumumab; papulopustular rash; skin toxicity.